These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 12243941)

  • 1. Who is fooling us?
    Sleight P; Yusuf S
    Lancet; 2002 Sep; 360(9336):873-4. PubMed ID: 12243941
    [No Abstract]   [Full Text] [Related]  

  • 2. Who is fooling us?
    Mourad JJ; Safar ME; O'Rourke MF
    Lancet; 2002 Jul; 360(9326):89. PubMed ID: 12114069
    [No Abstract]   [Full Text] [Related]  

  • 3. Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure.
    Fuchs FD
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):771-5. PubMed ID: 15350178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984
    [No Abstract]   [Full Text] [Related]  

  • 5. Is treatment of hypertension with acetylcholine esterase inhibitors (ACEIs) superior to other antihypertensives in preventing significant cardiovascular events and death in patients with type 2 diabetes?
    McConaghy JR
    J Fam Pract; 2000 Nov; 49(11):980. PubMed ID: 11093559
    [No Abstract]   [Full Text] [Related]  

  • 6. You should treat patients over the age of 80 who have hypertension.
    Lundberg GD
    Medscape J Med; 2008; 10(8):185. PubMed ID: 18924637
    [No Abstract]   [Full Text] [Related]  

  • 7. Implications and controversies of recent hypertension trials.
    Schwartz ML
    J Am Coll Cardiol; 2006 Aug; 48(4):848-9; author reply 849-50. PubMed ID: 16904567
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hypertension therapy for type 2 diabetics].
    Bönner G
    MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579
    [No Abstract]   [Full Text] [Related]  

  • 9. [Need of tight blood pressure control in type 2 diabetes. The intervention study ADVANCE gives clear information].
    Nilsson PM
    Lakartidningen; 2007 Oct 17-23; 104(42):3028-9. PubMed ID: 17985709
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of treatment of hypertension on cardiovascular outcome in type 2 diabetes.
    Migdalis IN
    Res Commun Mol Pathol Pharmacol; 2006; 119(1-6):105-14. PubMed ID: 17974100
    [No Abstract]   [Full Text] [Related]  

  • 11. Losartan versus ACE inhibitors in the treatment of hypertension.
    Jiang YC; Markind JE
    Ann Pharmacother; 1997 Nov; 31(11):1388-91. PubMed ID: 9391695
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative role of angiotensin receptor blockers versus other agents in the management of hypertension, cardiovascular disease and nephropathy.
    Tempelhof MW
    South Med J; 2009 Dec; 102(12):1201-2. PubMed ID: 20016423
    [No Abstract]   [Full Text] [Related]  

  • 13. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, ValHEFT, HOPE-TOO and SYST-EUR2).
    Lip GY; Beevers DG
    J Hum Hypertens; 2003 Nov; 17(11):747-50. PubMed ID: 14578913
    [No Abstract]   [Full Text] [Related]  

  • 14. [Control of arterial pressure in diabetic nephropathy].
    Luño J; García de Vinuesa S
    Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
    [No Abstract]   [Full Text] [Related]  

  • 15. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J
    J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE; Julius S
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
    MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157
    [No Abstract]   [Full Text] [Related]  

  • 19. [Hypertension in the elderly].
    Ogihara T
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():394-8. PubMed ID: 15171406
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials.
    Verdecchia P; Gentile G; Angeli F; Mazzotta G; Mancia G; Reboldi G
    J Hypertens; 2010 Jul; 28(7):1356-65. PubMed ID: 20375907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.